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The role of conventional protein kinase C (PKC) isoforms in the proliferation of a T cell lymphoma line was investigated. PKC isozyme-deficient 
cell lines were generated from HUT 78 which expresses PKC isoforms a, B, E and c. The first of these, K-4, expresses PKC u, E and 6 but not /I. 
L-2, a mutant of K-4, expresses PKC a and c but expresses neither PKC a, p, y, E nor c when cultured continuously in PMA (L-Z/PMA). All 
four cell lines continued to proliferate although at reduced rates in the presence of the PKC inhibitors staurosporine and H-7. K-4 and HUT 78 
undergo growth arrest when activated with PMA (rate of proliferation decreases by 76 and 95%, respectively). While PMA-induced growth arrest 
occurs in L-2 cells which possess PKC a and c, PMA-induced growth arrest does not occur in L-2/PMA which is deficient in these isoforms. As 
these cell lines continue to proliferate in the presence of PKC inhibitors and since proliferation occurs in the absence of PKC isoforms (L-Z/PMA), 
the results suggest hat neither conventional PKC nor the E and c isofonns are essential for proliferation of these cells. These data further suggest 
that PKC a and/or [ may be involved in PMA-induced growth arrest. 
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1. INTRODUCTION 
Protein kinase C (PKC) comprises a family of 
isoforms which may be divided into three major groups 
based on differences in enzymatic properties [I]. Many 
of these isoforms are activated by tumour promoters 
such as phorbol myristate acetate (PMA) which can 
mediate a range of intracellular functions [2,3]. Tumour 
promoters were first described by virtue of their ability 
to induce proliferation in resting cells in animal models 
of carcinogenesis [4]. Application of phorbol ester to 
mouse skin results in the development of cutaneous 
adenomas which can then be induced to malignant pro- 
liferation by the addition of a tumour induction agent. 
Resting T lymphocytes proliferate in the presence of 
phorbol esters and this proliferation is inhibited by 
PKC inhibitors [5]. However, many tumour cells un- 
dergo growth arrest when exposed to phorbol esters and 
this may be accompanied by differentiation. For exam- 
ple, in the HL60 cell line activation of protein kinase C 
through phorbol esters results in differentiation of the 
cell line to either a macrophage or a neutrophil lineage 
[6]. In addition, in K562 cells, the activation of PKC 
through phorbol esters results in differentiation to an 
erythrocyte lineage [7]. However, proliferation of cer- 
tain tumours has been shown to be arrested by PKC 
inhibitors [8] and it has been suggested that PKC inhib- 
itors may have a potential role as anti tumour agents [9]. 
The aim of this study was to investigate the role of PKC 
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in proliferation of human lymphoma cells. For this pur- 
pose we used the human T cell lymphoma line HUT 78 
and a mutant of this, K-4, which is deficient in PKC /I 
[lo]. From these cell lines we derived a number of vari- 
ants which were cloned lines deficient in known conven- 
tional and novel PKC isoforms. These mutants have 
been used to study the role of PKC isoforms in tumour 
proliferation. 
2. MATERIALS AND METHODS 
2.1. Materials and cells 
The HUT 78 cell line was obtained from ATCC. Antibodies to PKC 
isozymes cc, B and y were obtained from Seikagaku America, St. 
Petersburg, FL. Antibodies to PKC E and 6 and cell culture reagents 
were obtained from Gibco BRL, Gaithersburg, MD. PMA and Ge- 
nestein were obtained from Sigma, UK, and Staurosporine and H-7 
from Calbiochem, UK. Nitroblue tetrazolium (NBT) and 5-bromo-4- 
chloro-3-indolyl-phosphate (BCIP) were obtained from Promega 
Corp., Madison, WI. 
2.2. Cell culture 
Cells were grown in RPM1 1640 (CO, independent) supplemented 
with 10% heat-inactivated foetal calf serum, 2 mM L-glutamine, 100 
units/ml penicillin, lOO~g/ml streptomycin and 5 x lo-’ M 2-mercap- 
toethanol at 37°C. K-4 cells were generated as previously described 
[lo]. These cells were then cultivated in the presence of increasing 
concentrations of PMA (2&240 ng/ml) over a period of several weeks. 
Surviving cells were then cloned in complete medium containing 100 
@ml PMA at a concentration of 113 cell per well in the absence of 
feeder cells. The resultant cell line (L-2) was either maintained in 
complete medium or cultured continuously in the presence. of PMA 
(100 ng/ml). 
2.3. Flow cytometric analysis 
Cells were incubated with PMA (0,25, 50 and 100 &ml) for 24 h 
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and fixed in 0.5% (w/v) paraformaldehyde. Data were gathered using 
a Beckton Dickinson FACScan fluorescent cell analyser and forward 
scatter was analysed using Lysis II software. 
2.4. Thymidine incorporation assay 
Cells were incubated in 96-well flat-bottomed microtitre plates at 
a concentration of 2 x 10’ cells/well for 24 h and pulsed with tritiated 
thymidine (0.5 pCi/well) for the last 6 h of incubation. PMA (100 
@ml), PKC inhibitors at varying concentrations were added at the 
start of the incubation. Samples were harvested on a multiple auto- 
mated cell harvester and counted in a Packard liquid scintillation 
counter. 
2.5. Immunoblot studies 
Total cell extracts were prepared by solubilising the cells in 0.5% 
(w/v) Nonidet P-40 in PBS containing 1 mM PMSF and 10 &ml 
leupeptin. Proteins (100 pg) were separated by 10% SDS-PAGE and 
transferred to nitrocellulose [1 11. Non-specific binding sites were 
blocked with Blotto-Tween (5% non-fat dried milk containing 0.05% 
Tween-20 in PBS) for 1 h. The nitrocellulose membrane was then 
incubated with monoclonal or polyclonal (anti-peptide) antibody to 
the respective isozyme for 18 h. The membrane was then incubated 
with biotinylated sheep anti-mouse or donkey anti-rabbit antibody for 
1 h, followed by streptavidin-biotinylated alkaline phosphatase com- 
plex for 30 min. Immunoreactive bands were visual&d using Ni- 
troblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl-phos- 
phate (BCIP). Molecular weight marker proteins were localised by 
staining with 0.2% Ponseau-S in 3% trichloroacetic acid, 3% 
sulphosalicylic acid. 
3. RESULTS 
3.1. Generation of PKC isozyme-dejcient T cell lines 
A cell line K-4 was generated from HUT 78 as de- 
scribed previously [lo]. The K-4 cell line was cultured 
in increasing concentrations of PMA (20-240 &ml). 
An additional cell line, L-2, was cloned from K-4 cells 
which were resistant o 240 ng/ml PMA. L-2 cells were 
then maintained in continuous culture in the presence 
or absence of PMA. L-2 cells which proliferate in the 
continuous presence of PMA are designated L-2/PMA. 
PKC isoform expression in these cell lines was deter- 
mined by Western blot analysis (Fig. 1). The specific 
bands at approximately 90 kDa and 80 kDa for the 
polyclonal antibodies to E and 6 were abrogated by 
preincubation of these antibodies in blocking peptide. 
HUT 78 cells express the PKC isoforms CI, j?, E and c 
while K-4 express PKC IX, E and 5 but not PKC /3. The 
L-2 cell line expressed only PKC (r and c but L-2/PMA 
contain neither CI, /3, y, E nor 5. Thus, the L-2/PMA line 
is deficient in all conventional and novel PKC isoforms 
tested. Unfortunately PKC 6 could not be evaluated ue 
to the unsuitability of current available antibodies for 
detection of PKC 6 in these cell lines. While PKC 6 
could be detected clearly in rat brain, a persistent non- 
specific band at the appropriate molecular weight pre- 
vented detection in any of these cell lines. 
3.2. Proliferation of T cell lines 
Proliferation of the HUT 78 cell line was assessed by 
tritiated thymidine incorporation. Proliferation of HUT 
78 was inhibited at concentrations of 150 ,uM H-7 (Fig. 
244 
A 
L-2 
(W w (W W 
L-ZIPMA 
W (C) W w 
205 - 
116 - 
-wg7 - 
66 . 
45 - 
B 
PKC E 
(0 (8) W 0) 
PKCC + BP 
(0 (9) UV 0) 
PKC < PIE< + BP 
(1) (9) W 0) (0 (9) W (0 
Fig. 1. Western blot analysis of PKC isoform expression in HUT 78, 
K-4, L-2 and L-ZIPMA cells. (A) Classical PKC expression in L-2 and 
L-2/PMA cells; (a) PKC a, (b) PKCB, (c) PKC y, (d) isotype control, 
and (e) no antibody control. (B) PKC E and c expression in L-Z/PMA 
(f), L-2 (g), K-4 (h) and HUT 78 (i) determined in the presence and 
absence of the immunogenic (blocking) peptide. Relevant bands are 
indicated with an arrow. 
2). Proliferation of HUT 78 was significantly inhibited 
at a concentration of 1 x 10m7 M staurosporine which 
inhibited proliferation to approximately 40% of base- 
line values (Fig. 3). The PKC j? deficient K-4 cell line 
was not significantly inhibited by H-7 (Fig. 2), except 
at concentrations of 150 PM, when inhibition was ap- 
proximately 40%. Staurosporine produced a similar in- 
hibition of about 40%, which was considerably less than 
that induced in HUT 78 cells (Fig. 3). The rate of prolif- 
eration of the L-2 cell line was slightly reduced by H-7 
(150 PM) with an inhibition of 20% (Fig. 2). Stauro- 
sporine (0.15 PM) produced very little inhibition of pro- 
liferation of L-2 with continuing proliferation at 73% of 
basal levels (Fig. 3). The L-2/PMA cell line, which is 
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Fig. 2. Proliferation of T ceil clones in the PKC inhibitor H-7. HUT 
78, K-4, L-Z and L-ZIPMA cells were incubated in the presence of 
either 0, 50, 100 or 150 ,uM H-7 for 24 h. Rate of proliferation was 
measured as described in section 2.4. 
deficient in all PKC isoforms tested, was partially inhib- 
ited by H-7 and staurospo~ne (with PMA added to this 
medium). Proliferation continued at 80% and 66% of 
basal levels respectively (Figs. 2 and 3). 
PMA produced growth arrest in HuT 78 cells, result- 
ing in almost complete reduction of thymidine incorpo- 
ration (Fig. 4). PMA similarly produced a reduction in 
thymidine incorporation in the K-4 cell line, although 
not to the same extent as HUT 78. In the L-2 cell line, 
the reduction of proliferation with PMA was only 40% 
of the total cellular proliferation. In the L-2/PMA cell 
line there was little if any further inhibition of prolifera- 
tion with added PMA. The reduction in proliferation of 
the HUT 78 cell line and to a lesser extent K-4 and L-2 
represented apoptotic cell death and was reflected in a 
decrease in forward scatter (FSC) on flow cytometry 
(Fig. 5). In HUT 78 cells there was a reduction in FSC 
observed in the majority of cells. In the K-4 cell line 
there was clearly two populations, one of which showed 
a forward scatter shift consistent with apoptosis and a 
second which was resistant o PMA-induced apoptosis. 
Little change in FSC was seen in either L-2 cells or 
L-21PMA cells. Similar forward scatter profiles were 
observed over the PMA con~ntration range analysed 
(25-100 @ml). 
4. DISCUSSION 
The Protein kinase C family of enzymes comprises the 
conventional PKC isoforms 01, @ and y, the novel PKC 
isoforms S, E, q and @ and the atypical isoforms 6 and 
il [l]. PKC clearly plays a role in the proliferation of 
resting T cells, which can be blocked by incubation with 
PKC inhibitors [5]. Activators of PKC such as phorbol 
esters are also tumour promoters in multistage models 
of carcinogenesis. Calcinm flux is certainly synergistic 
with the effects of phorbol esters on T cell proliferation 
[12], suggesting an involvement of conventional protein 
kinase C isoforms as the novel PKC isoforms are fre- 
quently calcium independent and may indeed be inhib- 
ited by calcium [13]. It has been suggested that protein 
kinase C inhibitors may be useful in cancer chemother- 
apy on the basis of inhibition of proliferation of tumour 
cell lines [9]. Proliferation of the HUT 78 lymphoma cell 
line is partially inhibited by PKC inhibitors. However 
proliferation of HUT 78 is inhibited to a greater extent 
by activation of the protein kinase C enzyme by phorbol 
esters. The aim of this study was to determine whether 
conventional protein kinase C isoforms are necessary 
for proliferation. We have generated a panel of cloned 
lines derived from HUT ‘78 which are deficient in one or 
more PKC isoforms. The cell line L-2 is deficient in 
PKC B and E. Despite the fact that this cell line expresses 
PKC a, proliferation was not significantly inhibited by 
the PKC inhibitors, staurosporine or H-7. Furthermore 
the cell line L-2iPMA does not express PKC a, /3, y, E 
or {. Despite this, L-2/PMA inco~orated th~idine at 
levels comparable to the parent HUT 78 cell line. Thus 
we can conclude that none of these PKC isoforms are 
necessary for proliferation. 
The molecular weight of PKC c expressed in these 
cells is approximately 80 kDa, higher than the deduced 
molecular mass of 67 kDa [ 11. Characterisation of PKC 
C has shown it to lack a PMA-binding site and hence 
to be resistant o both translocation and down-regula- 
tion in response to PMA [14]. In our hands down-regu- 
0 Cells alone 
m 1X10-7 M Staur. 
0 1.5X10-7 M Staur. 
HuT78 K-4 L-2 L-BIPMA 
Pig. 3. Proliferation of T cell clones in the presence of the PKC 
inhibitor staurosporine. HuT 78, K4, L-2 and L-2iF’MA were incu- 
bated in the presence of0, 1 x lo-? M or 1.5 x 10S7 M staurosporine 
for 24 h. Rate of proliferation was assessed by [‘Hlthymidine incorpo- 
ration as described (section 2.4). 
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Fig. 4. Proliferation of T cell clones in phorbol myristate acetate 
(PMA). HUT 78, K-4, L-2 and L-2/PMA cells were incubated in the 
presence and absence of PMA (100 &ml) for 24 h. Rate of prolifer- 
ation was assessed by the rate of [‘Hlthymidine incorporation. 
lation of PKC 6 was not observed in short term culture 
(24 h) with PMA (data not shown). However, Tsutsumi 
et al. [15] describe an isoform of PKC 6 (PKC p’) in 
Jurkat cells which was down-regulated when cultured 
overnight in PMA and significantly reduced when these 
cells were cultured long term in PMA. Similarly, we 
A 
have observed significant down-regulation of this isoen- 
zyme on long-term culture of L-2 cells in the presence 
of PMA. It is unclear at what level this down-regulation 
occurs but it could conceivably represent a consequence 
of cross-talk between PKC isoforms. However, our data 
indicates that proliferation occurs in the absence of de- 
tectable PKC 5. It is possible however that isoforms of 
PKC such as PKC 6, q or 8 may be implicated in 
proliferation. Detection of PKC 6 in these cell lines has 
been inconclusive due to the presence of a cross reactive 
band at the predicted MW of PKC S using a commercial 
antibody. Since PKC 6, is partially resistant o inhibi- 
tion with both staurosporine and H-7 [16,17] and is 
universally distributed, this may be a candidate for in- 
volvement in proliferation. However, experiments 
where PKC 6 was overexpressed in CHO cells have 
suggested that this isoform may be involved in PMA- 
induced growth arrest rather than proliferation [18]. 
PMA-induced growth arrest occurs in a wide range 
of tumour types. It also occurs in thymocytes when this 
is manifested in apoptosis [19]. Striking growth arrest 
accompanied by cell death was observed in the HUT 78 
cell line. The decrease in forward scatter seen on flow 
cytometry suggests that this is mediated by apoptosis. 
In K-4 cells there was less growth arrest than in HUT 
78. Significantly the forward scatter plot shows two 
populations, one of which appears to be undergoing 
apoptosis while the second appears resistant. This is 
compatible with our finding that it was possible to sub- 
Fig. 5. Flow cytometric analysis. HUT 78 (A), K-4 (B), L-2 (C) and L-UPMA (D) were incubated in the presence (shaded) and absence (unshaded) 
of PMA (50 &ml). Cells were fixed and their forward scatter pattern analysed by flow cytometry. The forward scatter profiles for L-2/PMA in 
the presence and absence of PMA (D) are super-imposed. 
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clone PMA-resistant cells from K-4. Little forward scat- 
ter shift and growth arrest is seen in L-2 cells which are 
deficient in PKC p and E. However, the L-2/PMA cells, 
which are also deficient in PKC 01 and 5, do not show 
any growth arrest in response to PMA. These data pro- 
vide suggestive vidence that PKC a and 5 may be 
involved in growth arrest. The fact that these isoforms 
are universal lends further support for a common role 
in the regulation of the cell cycle. 
A number of studies have used overexpression of 
individual PKC isoforms to study effects on cell growth 
patterns. Overexpression of PKC #? results in altered 
pattern of growth in agar and increased tumourigenicity 
of fibroblast cell lines [20]. By contrast overexpression 
of this isoform resulted in reduced growth in the colonic 
tumour line HT29 [21]. Overexpression of PKC 6 has 
been reported to result in growth arrest in CHO cells 
1181. However increased expression of PKC S has been 
reported in regenerating hepatocytes [22]. It is clear that 
there is considerable variation in the effects of PKC 
overexpression in different cellular systems. However, 
our data suggest that in replicating lymphoma cells, 
there is considerable redundancy in the requirements of 
individual enzymes in proliferation. While PKC isoen- 
zymes may be implicated in cellular proliferation in the 
parent HUT 78 cell line, this is not an obligatory require- 
ment. These data suggest hat tumour therapy directed 
at inhibiting protein kinase C may be ineffective in the 
long term due to the selection of variant clones which 
do not utilise PKC in proliferation. Of greater interest 
however, may be the development of strategies based on 
PKC-induced growth arrest. Such strategies will require 
an expanded knowledge of the isoenzymes involved, 
their regulation and the receptors coupled to these 
isoenzymes. 
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